Albert W. Gianchetti
Director Ejecutivo en Xylocor Therapeutics, Inc. .
Perfil
Albert W.
Gianchetti is currently the President, Chief Executive Officer & Director at Xylocor Therapeutics, Inc. He previously worked as the Chief Commercial Officer & Senior Vice President at Vanda Pharmaceuticals, Inc. from 2007 to 2008 and as the Vice President-Global Commercial Strategy at GSK Plc.
He holds an MBA degree from Drexel University and an undergraduate degree from the University of Delaware.
Cargos activos de Albert W. Gianchetti
| Empresas | Cargo | Inicio |
|---|---|---|
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director Ejecutivo | - |
Antiguos cargos conocidos de Albert W. Gianchetti.
| Empresas | Cargo | Fin |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/12/2008 |
| GSK PLC | Corporate Officer/Principal | - |
Formación de Albert W. Gianchetti.
| University of Delaware | Undergraduate Degree |
| Drexel University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| GSK PLC | Health Technology |
| Empresas privadas | 1 |
|---|---|
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Albert W. Gianchetti
